Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B

doi:10.4254/wjh.v17.i5.106916

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (199)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

HTML

114

Figures (1-5)

Tables (1-2)

Sum=157

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=26

May 27, 2025 (publication date) through May 30, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Hepatol. May 27, 2025; 17(5): 106916
Published online May 27, 2025. doi: 10.4254/wjh.v17.i5.106916

Table 1 Baseline characteristics of 346 study participants, n (%)/means ± SE/median (min-max)

Variable	CHB patients (n = 346)
Sex
Male	206 (59.5)
Female	140 (40.5)
Age (years)	42.6 ± 0.65
Fibrosis stage (n)
F0	37
F1	83
F2	105
F3	48
F4	73
Fibroscan (kPa)	7.7 (0.4-46.5)
Platelet count (10⁹/L)	213 (49-394)
AST (µl/L)	29 (12.9-235.6)
ALT (µl/L)	31.9 (6.2-191.8)
Hemoglobin (g/L)	14.5 (4.6-18.4)
WBC (10⁹/L)	6.6 (3.6-15.8)
M2BPGi (C.O.I)	1.02 (0.19-12.9)
FIB-4	1.0 (0.32-11.3)
APRI	0.38 (0.11-6.93)

CHB: Chronic hepatitis B; AST: Aspartate transaminase; ALT: Alanine transaminase; WBC: White blood counts; C.O.I: Cut-off index; FIB-4: Fibrosis-4 index; M2BPGi: Mac-2 binding protein glycosylated isomer; APRI: Aspartate transaminase to platelet ratio index.

Table 2 Baseline major markers of 346 study participants in various fibrosis stages, median (interquartile range)/means ± SD

Variable	F0 (n = 37)	F1 (n = 83)	F2 (n = 105)	F3 (n = 48)	F4 (n = 73)	Overall P value (< 0.05)
Male/Female	12/25	40/43	69/36	31/17	54/19
Age (years)	37 ± 8.6	40 ± 10.8	41.1 ± 11.6	44.2 ± 12.0	48.1 ± 13.2	< 0.0001
Platelet (10⁹/L)	232.0 (202.5-260)	235 (210-275)	212 (184.8-244.5)	191 (166.5-252.8)	167 (130.5-207.5)	< 0.0001
AST (IU/L)	21.8 (18.7-25.3)	23.4 (19.5-26.5)	34.4 (26.3-47.8)	40.1 (28.6-57.3)	45.0 (35.4-73.4)	< 0.0001
ALT (IU/L)	23.1 (14.6-26.9)	21.7 (16.4-27.1)	39.0 (27.6-67.4)	49.9 (37.0-76.3)	52.3 (33-73)	< 0.0001
Hemoglobin (g/L)	13.8 (13.1-15)	14.3 (13.5-15.5)	14.8 (13.9-15.9)	14.6 (13.7-16.2)	14.7 (13.7-16.1)	0.006
WBC (10⁹/L)	6.4 (5.8-7.9)	6.5 (5.8-7.5)	6.7 (5.5-8.5)	6.8 (6.0-8.3)	6.5 (5.6-8.1)	0.621
Fibroscan (kPa)	4.6 (4-4.9)	6.0 (5.5-6.4)	7.8 (7.5-8.4)	10.5 (9.8-11.5)	22.3 (17.3-31.6)	< 0.0001
M2BPGi (C.O.I)	0.66 (0.51-1)	0.76 (0.51-1.01)	0.93 (0.74-1.34)	1.54 (1.13-1.94)	3.2 (1.56-3.9)	< 0.0001
FIB-4	0.74 (0.58-0.94)	0.83 (0.65-1.03)	1.08 (0.75-1.5)	1.28 (0.93-2.2)	2.18 (1.5-3.4)	< 0.0001
APRI	0.25 (0.21-0.31)	0.26 (0.21-0.33)	0.47 (0.34-0.72)	0.68 (0.43-1.1)	1.37 (0.69-3.19)	< 0.0001

AST: Aspartate transaminase; ALT: Alanine transaminase; WBC: White blood cell; C.O.I: Cut-off Index; FIB-4: Fibrosis-4 index; M2BPGi: Mac-2 binding protein glycosylated isomer; APRI: Aspartate transaminase to platelet ratio index.

Citation: Pham TTT, Ho DT, Phan HT, Nguyen TB, Nguyen KM. Assessing the role of Mac-2 binding protein glycosylation isomer in the management of patients with chronic hepatitis B. World J Hepatol 2025; 17(5): 106916
URL: https://www.wjgnet.com/1948-5182/full/v17/i5/106916.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i5.106916